The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

"The noninferior effect of tirzepatide as compared with dulaglutide on the primary cardiovascular outcome provides additional ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

Tirzepatide has quickly become one of the most talked-about medications in the weight loss space. Originally developed to treat type 2 diabetes, it has shown significant results in helping people lose ...

Please provide your email address to receive an email when new articles are posted on . Baseline BMI may impact treatment effect of tirzepatide in patients with HFpEF and obesity. Distribution of ...

In today’s fast-paced world, managing weight and metabolic health has become a crucial concern for many. With the rise of obesity and related health issues, effective solutions are in high demand.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease. In China, rising rates of overweight and ...

Over the last few years, there has been an increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for weight loss. Both Mounjaro and Zepbound are produced by the ...

Researchers found that women with hypertension who followed a very low-calorie ketogenic diet had lower systolic and diastolic blood pressure at 6 months than those who participated in intermittent ...

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...

Tirzepatide and semaglutide would have to drop their current net prices by 30.5% and 81.9%, respectively, to be cost-effective. Over a lifetime of use, tirzepatide could avert 45,609 obesity cases, 20 ...

USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...